Is Litigation on the Horizon for Sunscreen Manufacturers?

Posted by Crista Trippodi Murphy on Posted on

On May 6, 2019, a study published in the Journal of the American Medical Association reported that several sunscreens used under maximal conditions resulted in plasma concentrations of active ingredients that exceeded the threshold limit established by the U.S. Food and Drug Administration (FDA). The fact that an ingredient is absorbed through the skin and
Read More

New PFAS Legislation Will Have Big Impact on Litigation

Posted by Crista Trippodi Murphy on Posted on

Recently, both the U.S. House of Representatives and Senate held separate legislative hearings to address potential health and environmental impacts of pre-/polyfluorinated substances (PFAS). On May 15, 2019, the House Subcommittee on Environment and Climate Change held a hearing to consider a series of bills aimed at reducing potential environmental and health risks associated with
Read More

Can Smoking Cause Mesothelioma?

Posted by Crista Trippodi Murphy on Posted on

The causal relationship between smoking and lung cancer is one of the strongest and most well established in all the health sciences. Asbestos defense attorneys have therefore been eager to determine if there is a causal relationship between smoking and mesothelioma. If such a relationship were identified, in certain cases with the right case-specific facts,
Read More

New Study Identifies Potential Genetic Biomarker of Malignant Pleural Mesothelioma

Posted by Crista Trippodi Murphy on Posted on

In a recently published article, Guarrera and colleagues report differential DNA methylation between malignant pleural mesothelioma (MPM) patients and cancer-free controls. These data represent some of the first evidence of detectable differences in DNA methylation in asbestos-exposed individuals with and without MPM. For asbestos defendants, these results provide support for the potential use of DNA
Read More

Malignant Mesothelioma in Women: Non-Occupational Asbestos Exposure or Genetics?

Posted by Crista Trippodi Murphy on Posted on

A recent article by Marinaccio and colleagues examined gender differences and modalities of asbestos exposure in malignant mesothelioma (MM). The results are some of the first to examine gender differences in mesothelioma risk, with significantly more cases of MM attributed to occupational asbestos exposure in men than women. The author concluded that non-occupational exposure to
Read More

No Ginger in Ginger Ale – “Nuisance Litigation” Against Food Manufacturers Continues to Rise

Posted by Crista Trippodi Murphy on Posted on

On July 10, 2018, a federal lawsuit was filed contending that Canada Dry and its parent company Dr. Pepper Snapple, Inc. misled customers by falsely advertising “Made from Real Ginger”. This suit is the latest among several brought against the company asserting that customers believed Canada Dry Ginger Ale to have health benefits because it
Read More

New Jersey Adopts Stricter Standards for Admissibility of Expert Testimony

Posted by Crista Trippodi Murphy on Posted on

On August 1, 2018, the New Jersey State Supreme Court handed down a landmark decision when they unanimously voted to adopt stricter standards for expert testimony, affirming the court’s role as the “gatekeeper of scientific evidence”. Expert Testimony Properly Excluded The court’s ruling is a direct result of ongoing litigation surrounding claims that the prescription
Read More

Biosimilar Patent Litigators Can Benefit from the Right Consulting and Testifying Experts

Posted by Crista Trippodi Murphy on Posted on

The commercialization of biosimilars was enabled by the Biologics Price Competition and Innovation Act (BPCIA) of 2009 which was signed into law on March 22, 2010 as part of the Patient Protection and Affordable Care Act. Biologics are produced using living organisms, and thus, are usually much more complex than most small molecule drugs. Biosimilars
Read More

The Importance of Genetics Experts in Pharmaceutical Litigation

Posted by Crista Trippodi Murphy on Posted on

A Case Study from the Testosterone Litigation A recent defense verdict in the testosterone litigation highlights the importance of genetics in pharmaceutical litigation. In this case, neither the plaintiffs nor the defense called a geneticist as an expert, yet both sides tried to use genetic arguments in their case. In this post we summarize the
Read More

Protein-based adverse drug reactions (ADRs): Using proteomics to assess drug safety

Posted by Crista Trippodi Murphy on Posted on

Each year, adverse drug events cost millions of dollars in hospital admissions, injuries to patients, and malpractice. And companies spend billions of dollars on litigation involving allegations that their drugs caused adverse drug reactions (ADRs). What if there was a better way to determine individualized drug adverse events? Welcome to the Age of Proteomics The
Read More